Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Feb;67(2):237–243. doi: 10.1038/bjc.1993.46

Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers.

H Kobayashi 1, H Ohi 1, T Fujii 1, T Terao 1
PMCID: PMC1968183  PMID: 7679280

Abstract

A new cancer-associated antigen CA130, recognised by two monoclonal antibodies (moABs) 130-22 and 145-9, was often found to be present at high levels in the sera of patients with ovarian cancer. There was a strong correlation between CA130 and CA125 values. The epitopes recognised by moABs 130-22 and 145-9 were proved to differ from the CA125 epitope, but to exist on the molecule bearing CA125. Unlike OC125, the majority of 130-22/145-9 activity was associated with a much lower molecular mass (less than 200 kDa), indicating that a lower molecular mass immunoreactive determination may be a unique CA130 antigenic determinant within CA125 molecule. Clinical data demonstrate that, (1) elevated levels of CA130 determinant were found in the sera of 91.3% of women with epithelial ovarian cancer, (2) falling or rising levels of CA130 correlated with regression or progression of ovarian cancer in > 95% of cases, (3) normalisation of serum CA130 levels at response does not imply no microscopic residual disease, but CA130 changes during follow-up support the evaluation of recurrence and can be used as a monitoring marker in an individual patient.

Full text

PDF
237

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  3. Buller R. E., Berman M. L., Bloss J. D., Manetta A., DiSaia P. J. CA 125 regression: a model for epithelial ovarian cancer response. Am J Obstet Gynecol. 1991 Aug;165(2):360–367. doi: 10.1016/0002-9378(91)90093-7. [DOI] [PubMed] [Google Scholar]
  4. Canney P. A., Moore M., Wilkinson P. M., James R. D. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 1984 Dec;50(6):765–769. doi: 10.1038/bjc.1984.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davis H. M., Zurawski V. R., Jr, Bast R. C., Jr, Klug T. L. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res. 1986 Dec;46(12 Pt 1):6143–6148. [PubMed] [Google Scholar]
  6. Fujii T. [Establishment and characterization of human ovarian endometrioid carcinoma cell line]. Nihon Sanka Fujinka Gakkai Zasshi. 1989 Feb;41(2):161–166. [PubMed] [Google Scholar]
  7. Hakomori S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res. 1985 Jun;45(6):2405–2414. [PubMed] [Google Scholar]
  8. Herlyn M., Sears H. F., Steplewski Z., Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol. 1982 Apr;2(2):135–140. doi: 10.1007/BF00916897. [DOI] [PubMed] [Google Scholar]
  9. Imai S., Kiyozuka Y., Maeda H., Noda T., Hosick H. L. Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. Oncology. 1990;47(2):177–184. doi: 10.1159/000226813. [DOI] [PubMed] [Google Scholar]
  10. Imai S., Maeda H., Kiyozuka Y., Noda T., Moriyama I., Ichijo M. Characterization of the CA125 antigen secreted from a newly established human ovarian cancer cell line (SHIN-3). Acta Pathol Jpn. 1989 Jan;39(1):43–49. doi: 10.1111/j.1440-1827.1989.tb02401.x. [DOI] [PubMed] [Google Scholar]
  11. Inaba N., Okajima Y., Ota Y., Fukazawa I., Yamaguchi T., Sato N., Sudo H., Milanga M., Takamizawa H., Fujii S. [A fundamental and clinical investigation of cancer antigen 130 (CA 130) in the field of obstetrics and gynecology]. Nihon Gan Chiryo Gakkai Shi. 1989 Oct 20;24(10):2426–2435. [PubMed] [Google Scholar]
  12. Itzkowitz S. H., Bloom E. J., Kokal W. A., Modin G., Hakomori S., Kim Y. S. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer. 1990 Nov 1;66(9):1960–1966. doi: 10.1002/1097-0142(19901101)66:9<1960::aid-cncr2820660919>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  13. Itzkowitz S. H., Yuan M., Montgomery C. K., Kjeldsen T., Takahashi H. K., Bigbee W. L., Kim Y. S. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 1989 Jan 1;49(1):197–204. [PubMed] [Google Scholar]
  14. Kivinen S., Kuoppala T., Leppilampi M., Vuori J., Kauppila A. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma. Obstet Gynecol. 1986 Apr;67(4):468–472. [PubMed] [Google Scholar]
  15. Klug T. L., Bast R. C., Jr, Niloff J. M., Knapp R. C., Zurawski V. R., Jr Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. 1984 Mar;44(3):1048–1053. [PubMed] [Google Scholar]
  16. Kobayashi H., Terao T., Kawashima Y. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer. J Clin Oncol. 1991 Jun;9(6):983–987. doi: 10.1200/JCO.1991.9.6.983. [DOI] [PubMed] [Google Scholar]
  17. Kuzuya K., Nozaki M., Chihara T. Evaluation of CA125 as a circulating tumor marker for ovarian cancer. Nihon Sanka Fujinka Gakkai Zasshi. 1986 Jun;38(6):949–957. [PubMed] [Google Scholar]
  18. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  19. Lavin P. T., Knapp R. C., Malkasian G., Whitney C. W., Berek J. C., Bast R. C., Jr CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol. 1987 Feb;69(2):223–227. [PubMed] [Google Scholar]
  20. Matsubara Y., Shiota T., Ishida H., Hanawa T., Yagi K., Kosaba S., Hatakenaka R., Funatsu T., Ikeda S. [Clinical evaluation of serum CA130 in patients with lung cancer]. Nihon Gan Chiryo Gakkai Shi. 1989 Aug 20;24(8):1557–1565. [PubMed] [Google Scholar]
  21. Matsuoka Y., Nakashima T., Endo K., Yoshida T., Kunimatsu M., Sakahara H., Koizumi M., Nakagawa T., Yamaguchi N., Torizuka K. Recognition of ovarian cancer antigen CA125 by murine monoclonal antibody produced by immunization of lung cancer cells. Cancer Res. 1987 Dec 1;47(23):6335–6340. [PubMed] [Google Scholar]
  22. Mogensen O., Mogensen B., Jakobsen A. Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer. Gynecol Oncol. 1990 Apr;37(1):44–46. doi: 10.1016/0090-8258(90)90305-5. [DOI] [PubMed] [Google Scholar]
  23. Niloff J. M., Knapp R. C., Lavin P. T., Malkasian G. D., Berek J. S., Mortel R., Whitney C., Zurawski V. R., Jr, Bast R. C., Jr The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol. 1986 Jul;155(1):56–60. doi: 10.1016/0002-9378(86)90077-3. [DOI] [PubMed] [Google Scholar]
  24. Niloff J. M., Knapp R. C., Schaetzl E., Reynolds C., Bast R. C., Jr CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol. 1984 Nov;64(5):703–707. [PubMed] [Google Scholar]
  25. Pittaway D. E., Fayez J. A. The use of CA-125 in the diagnosis and management of endometriosis. Fertil Steril. 1986 Nov;46(5):790–795. doi: 10.1016/s0015-0282(16)49812-2. [DOI] [PubMed] [Google Scholar]
  26. Rubin S. C., Hoskins W. J., Hakes T. B., Markman M., Reichman B. S., Chapman D., Lewis J. L., Jr Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol. 1989 Mar;160(3):667–671. doi: 10.1016/s0002-9378(89)80054-7. [DOI] [PubMed] [Google Scholar]
  27. Schilthuis M. S., Aalders J. G., Bouma J., Kooi H., Fleuren G. J., Willemse P. H., De Bruijn H. W. Serum CA 125 levels in epithelial ovarian cancer: relation with findings at second-look operations and their role in the detection of tumour recurrence. Br J Obstet Gynaecol. 1987 Mar;94(3):202–207. doi: 10.1111/j.1471-0528.1987.tb02354.x. [DOI] [PubMed] [Google Scholar]
  28. Springer G. F. T and Tn, general carcinoma autoantigens. Science. 1984 Jun 15;224(4654):1198–1206. doi: 10.1126/science.6729450. [DOI] [PubMed] [Google Scholar]
  29. Vergote I. B., Børmer O. P., Abeler V. M. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol. 1987 Jul;157(1):88–92. doi: 10.1016/s0002-9378(87)80352-6. [DOI] [PubMed] [Google Scholar]
  30. Zanaboni F., Vergadoro F., Presti M., Gallotti P., Lombardi F., Bolis G. Tumor antigen CA 125 as a marker of ovarian epithelial carcinoma. Gynecol Oncol. 1987 Sep;28(1):61–67. doi: 10.1016/s0090-8258(87)80009-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES